Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|October 24, 2018
Analysis of Synthetic Cannabinoid Metabolites by Liquid Chromatography-Tandem Mass SpectrometryGregory C JanisMethods in Molecular Biology (Clifton, N.J.)|October 24, 2018
Salt-Assisted Liquid-Liquid Extraction of Meconium for Analysis of Cocaine and Amphetamines by Liquid Chromatography-Tandem Mass SpectrometryMelissa M Goggin, Gregory C JanisMethods in Molecular Biology (Clifton, N.J.)|July 7, 2012
Analysis of selected anticonvulsants by high performance liquid chromatography-tandem mass spectrometryJennifer A Collins, Gregory C JanisClinical Toxicology (Philadelphia, Pa.)|October 29, 2020
Using measured cannabidiol and tetrahydrocannabinol metabolites in urine to differentiate marijuana use from consumption of commercial cannabidiol productsMelissa M Goggin, Gregory C JanisJournal of Analytical Toxicology|October 2, 2012
Analysis of mitragynine and metabolites in human urine for detecting the use of the psychoactive plant kratomDavid Le, Melissa M Goggin, Gregory C JanisJournal of Analytical Toxicology|April 4, 2017
Identification of Unique Metabolites of the Designer Opioid Furanyl FentanylMelissa M Goggin, An Nguyen, Gregory C JanisAlcoholism, Clinical and Experimental Research|January 12, 1999
Effects of chronic ethanol consumption and withdrawal on the neuroactive steroid 3alpha-hydroxy-5alpha-pregnan-20-one in male and female ratsG C Janis, L L Devaud, H Mitsuyama, et al.Pain Management|September 10, 2019
Reduced urinary opioid levels from pain management patients associated with marijuana useMelissa M Goggin, Breane J Shahriar, Andy Stead, et al.Journal of Analytical Toxicology|February 23, 2018
Anodyne by Design; Measuring the Prevalence of Esoteric Designer Opioids in Pain Management PatientsMelissa M Goggin, Stephanie D Gozum, Anna Miller, et al.Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology|July 23, 2013
2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testingSamuel J Stellpflug, Samantha E Kealey, Cullen B Hegarty, et al.Pageof 3